US Nuclear’s Medical Isotope Production to Revolutionize Healthcare
LOS ANGELES, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) — via NewMediaWire –One of the most critical problems faced by the healthcare industry worldwide is the severe shortage of radionuclides for nuclear medicine, imaging, diagnosis, and treatment. US Nuclear’s (OTC-QB: UCLE) plan to bring medical isotopes to the market will reshape the landscape of healthcare and diagnostic imaging.
Related news for (UCLE)
- US Nuclear Corp. Announces First Quarter 2024 Results
- US Nuclear’s Unparalleled PFAS Monitoring Products in Spotlight as EPA Sets First-Ever Limits on PFAS
- US Nuclear Delivers First Batch of Tritium Monitoring Systems to Nation’s Largest Public Power Company
- US Nuclear’s Overhoff Delivers the Goods to U.S. DOE
- US Nuclear’s Overhoff Branch is Fusion Energy’s Go-To Tritium Monitoring Solution